XOMA Corp (XOMA) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.003x

Based on the latest financial reports, XOMA Corp (XOMA) has a cash flow conversion efficiency ratio of -0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-296.00K) by net assets ($107.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

XOMA Corp - Cash Flow Conversion Efficiency Trend (1989–2024)

This chart illustrates how XOMA Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read XOMA Corp total liabilities for a breakdown of total debt and financial obligations.

XOMA Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of XOMA Corp ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Novabase SGPS
LS:NBA
0.059x
enCore Energy Corp.
V:EU
-0.073x
eDreams Odigeo SA
MC:EDR
0.066x
SNDL INC.
F:VY4
0.021x
Hiyes International Co Ltd
TW:2348
0.008x
BGF Retail Co Ltd
KO:027410
0.004x
Alfas Solar Enerji Sanayi ve Ticaret A.S.
IS:ALFAS
0.291x
Daishin Securities Co Ltd Pref
KO:003545
-0.415x

Annual Cash Flow Conversion Efficiency for XOMA Corp (1989–2024)

The table below shows the annual cash flow conversion efficiency of XOMA Corp from 1989 to 2024. For the full company profile with market capitalisation and key ratios, see XOMA market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $81.92 Million $-13.75 Million -0.168x +18.00%
2023-12-31 $88.72 Million $-18.16 Million -0.205x -97.07%
2022-12-31 $124.01 Million $-12.88 Million -0.104x -164.97%
2021-12-31 $141.88 Million $22.68 Million 0.160x +36.88%
2020-12-31 $86.42 Million $10.09 Million 0.117x +1902.32%
2019-12-31 $43.99 Million $-285.00K -0.006x +99.04%
2018-12-31 $18.79 Million $-12.64 Million -0.673x -244.99%
2017-12-31 $5.79 Million $2.69 Million 0.464x -34.95%
2016-12-31 $-47.21 Million $-33.69 Million 0.714x -94.67%
2015-12-31 $-2.31 Million $-30.89 Million 13.379x +152.96%
2014-12-31 $3.10 Million $-78.28 Million -25.260x -319.35%
2013-12-31 $-3.99 Million $-45.91 Million 11.516x +706.45%
2012-12-31 $21.47 Million $-40.77 Million -1.899x +1.92%
2011-12-31 $15.01 Million $-29.06 Million -1.936x +13.06%
2010-12-31 $23.59 Million $-52.54 Million -2.227x -624.95%
2009-12-31 $17.53 Million $7.43 Million 0.424x -59.60%
2008-12-31 $-31.40 Million $-32.98 Million 1.050x -92.65%
2007-12-31 $318.00K $4.54 Million 14.286x +1539.15%
2006-12-31 $-38.17 Million $-33.27 Million 0.872x -59.23%
2005-12-31 $-20.67 Million $-44.19 Million 2.138x +17.36%
2004-12-31 $-24.61 Million $-44.83 Million 1.821x +284.74%
2003-12-31 $48.21 Million $-47.54 Million -0.986x -132.16%
2002-12-31 $-11.37 Million $-34.84 Million 3.066x +286.21%
2001-12-31 $13.62 Million $-22.42 Million -1.646x -162.96%
2000-12-31 $-8.59 Million $-22.46 Million 2.615x +2.53%
1999-12-31 $-16.90 Million $-43.10 Million 2.550x +101.35%
1998-12-31 $200.00K $-37.70 Million -188.500x -48910.00%
1997-12-31 $31.20 Million $-12.00 Million -0.385x +40.42%
1996-12-31 $34.70 Million $-22.40 Million -0.646x +40.14%
1995-12-31 $26.80 Million $-28.90 Million -1.078x -64.59%
1994-12-31 $43.50 Million $-28.50 Million -0.655x -77.74%
1993-12-31 $78.40 Million $-28.90 Million -0.369x +4.61%
1992-12-31 $88.50 Million $-34.20 Million -0.386x -88.32%
1991-12-31 $134.50 Million $-27.60 Million -0.205x +76.03%
1990-12-31 $26.40 Million $-22.60 Million -0.856x -26.77%
1989-12-31 $27.10 Million $-18.30 Million -0.675x --

About XOMA Corp

NASDAQ:XOMA USA Biotechnology
Market Cap
$512.41 Million
Market Cap Rank
#14434 Global
#3255 in USA
Share Price
$41.38
Change (1 day)
+1.07%
52-Week Range
$22.89 - $41.97
All Time High
$45.61
About

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential… Read more